International Journal of Clinical Pharmacology and Therapeutics, Vol. 50 – No. 3/2012 (224-232)
A positron emission tomography microdosing
study with sertraline in healthy volunteers
Original
©2012 Dustri-Verlag Dr. K. Feistle
ISSN 0946-1965
DOI 10.5414/CP201644
e-pub: February 27, 2012
Key words
microdosing – CNS drug
– positron emission
tomography – pharmacokinetics – sertraline
Received
August 16, 2011;
accepted
October 19, 2011
Correspondence to
Kyung-Sang Yu,
MD, PhD
Assistant Professor of
Clinical Pharmacology,
College of Medicine,
Seoul National
University Clinical Trials
Center, Seoul National
University Hospital, 101
Daehangno, Jongno-gu,
Seoul, 110-744 Korea
happyi69@snu.ac.kr
Kwang-Hee Shin1, Kyu-pyo Kim1, Kyoung Soo Lim1, Ji Who Kim2, Yun-Sang Lee2,
Bo Yeun Yang2, Jae Sung Lee2, Jae-Min Jung2, Seo-Hyun Yoon1, In-Jin Jang1 and
Kyung-Sang Yu1
1
Department of Pharmacology and Clinical Pharmacology, Seoul National University
College of Medicine and Hospital, and 2Department of Nuclear Medicine, Seoul
National University College of Medicine and Hospital, Seoul, Korea
Abstract. Objective: This study explored
microdosing methods for evaluating the distribution and pharmacokinetics (PK) of a
central nervous system (CNS) drug candidate. Methods: We used sertraline as a model
drug. In this open-label, one-arm, three-period, multiple-dosing study, 10 healthy male
volunteers received 6-day administrations of
sertraline at doses of 5, 25 or 50 mg/d in three
different periods. Before the first dose of Period 1, and 24 h after the last dose of each period, an intravenous bolus of [11C]sertraline
was injected for positron emission tomography (PET) scanning. After the sixth dose in
each period, serial blood samples were collected at scheduled intervals over 48 h; then
serum sertraline concentrations were determined with liquid chromatography-tandem
mass spectrometry (LC-MS/MS). Results:
Sertraline was distributed in the brain within
20 min, and it was highly distributed in the
putamen, cingulate, and thalamus. Linearity in steady-state Cmax and AUClast were
observed in the 5 – 50 mg dose range. The
results suggested that microdosing with PET
was a useful method for exploring the bloodbrain-barrier penetration and distribution of
a candidate CNS drug. Conclusions: This
study described a microdosing method that
combined PET with LC-MS/MS for determining the brain distribution and PK characteristics of a CNS drug candidate.
Introduction
In drug development, human microdosing studies are conducted at an early stage
to evaluate the basic pharmacokinetics or
distribution characteristics of a novel drug. A
microdose is defined as 1/100th of the pharmacological dose determined from modeling
studies, or 100 µg, whichever is smaller. The
dose is intentionally small to avoid producing a pharmacological effect or adverse reactions in humans [1]. Previous studies have
proposed methods for microdosing that employed highly sensitive techniques, including accelerator mass spectrometry (AMS)
or positron emission tomography (PET) [8,
12]. Guidelines for these exploratory clinical trials have been issued by regulatory authorities; the European Medicines Agency
issued the “Position paper on non-clinical
safety studies to support clinical trials with
a single microdose” in 2004 [1]; the Federal
Drug Administration issued guidelines for
“Exploratory IND studies” in 2006 [4]; and
the International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use
(ICH) issued the M3 guideline “Guidance on
nonclinical safety studies for the conduct of
human clinical trials and marketing authorization for pharmaceuticals” in 2008 [3].
Several microdosing studies have aimed
at evaluating the predictability of these microdose methods for determining the pharmacokinetic and/or pharmacodynamic characteristics of known drugs [6, 26, 29, 31].
They were conducted with doses that ranged
from a microdose to a therapeutic dose.
Those studies used PET scanning with a radio-labeled drug, AMS, or liquid chromatography-tandem mass spectrometry (LC-MS/
MS) methods. They reported “lower limits of
quantification (LLOQ)” that were lower than
those reported in other studies. More recently, microdosing studies have been conducted
for newly developed drugs [7, 14]. For example, an underdeveloped drug for Alzheimer’s disease was investigated in a microdos-
225
A PET microdosing study with sertraline
ing study with PET imaging to explore drug
biodistribution and characteristics [7].
Drugs that target areas in the central nervous system (CNS) must penetrate the blood
brain barrier (BBB) and reach the appropriate brain region to provide sufficient brain
exposure. Over 98% of small molecules do
not effectively pass the BBB, which results
in inadequate brain exposure [23] and failure in drug development [27]. Therefore,
CNS drug development would benefit from a
microdosing approach for predicting the biodistributions and pharmacokinetic profiles of
novel drugs in early phase clinical trials [7].
Sertraline (Zoloft®, Pfizer, New York, NY,
USA), an antidepressant, is a selective serotonin (5-hydroxytryptamine, 5-HT) reuptake
inhibitor (SSRI) that targets receptors in the
CNS. Many studies have characterized the
pharmacokinetics and pharmacodynamics of
sertraline. Sertraline reached maximum concentration at 4 – 8 h after oral administration
and was eliminated with a 22 – 36 h half-life.
A linear pharmacokinetic profile was reported for the 50 – 200 mg dose range [30]. The
therapeutically effective dose of sertraline
was 50 mg/d, which inhibited serotonin uptake by 76 – 80% [11, 28].
The present study explored the potential of the microdose method for predicting
the distribution and pharmacokinetic characteristics of CNS drug candidates. Since
this study was intended as a method exploration study rather than an actual study
in a new drug candidate, we selected a
compound which is already authorized for
marketing and of which the pharmacological properties are relatively well known.
Among the conventional drugs, we used
sertraline as a model CNS drug for purposes of this study.
Subjects and methods
Subjects
Within 3 weeks of the first drug administration, all subjects were evaluated with a
physical examination that included a neurological examination, measurement of vital
signs, a 12-lead electrocardiogram (ECG),
serology, a urine screen for drug abuse and
routine clinical laboratory tests. Subjects
were excluded when they met the following exclusion criteria: history of significant
clinical illness that required medical caution, including cardiovascular, immunologic,
hematologic, neuropsychiatric, respiratory,
gastrointestinal, hepatic or renal disease or
other chronic disease; a history or evidence
of drug abuse; use of any prescription medication or OTC medication. The subjects’
medical and alcohol/medicine abuse histories were accessed in an interview conducted
by investigators and by the subject’s self-report. And additional urinary drug testing was
performed within 3 weeks of the first administration of the study drug.
Eleven eligible healthy Korean male
volunteers were enrolled. Each volunteer
gave written informed consent before enrollment. The study protocol was approved
by the Institutional Review Board of Seoul
National University Hospital. All procedures
were performed in accordance with the International Conference on Harmonization of
Technical Requirements for Registration of
Pharmaceuticals for Human Use-Good Clinical Practices [2] and the recommendations
of the Declaration of Helsinki on biomedical
research involving human subjects [5].
Study design
This was an open-label, three-period,
single sequence, multiple-dosing study. The
study consisted of three consecutive treatment periods of 7 days each, with no washout in between doses. Each treatment period
comprised a daily, oral, single dose of sertraline for 6 days. On the 7th day of each period,
no dose was given, and the PET scan was
performed. The doses increased each treatment period, starting with 5 mg in the first,
25 mg in the second and 50 mg in the third
period. Subjects were prohibited from using
any drugs within 7 days prior to the study.
On the 6th day of each study period, sertraline was given after overnight-fasting, and
the subject maintained the semi-fowler position and a fasting state until 4 h after drug
administration. Each dose was administered
with 240 ml of water. Serial blood samples
were drawn over the next 48 h for pharmacokinetic analyses.
226
Shin, Kim, Lim et al.
Before the first oral sertraline administration of Period 1 (baseline), and 24 h after the
last dose of each period, an intravenous, microdose bolus of [11C]sertraline was administered, and the PET scan was performed.
Synthesis of [11C]sertraline
[11C]sertraline was prepared in the Department of Nuclear Medicine, Seoul National University Hospital, according to a
published method [19]. Briefly, [11C]carbon
dioxide was produced by irradiating nitrogen gas with 13 MeV of protons with the
TR13 cyclotron (EBCO. Co., Richmond,
BC, Canada). [11C]methyl iodide was produced from lithium aluminum hydride and
hydroiodide [10]. Distilled [11C]methyl iodide was passed through a preheated (230
°C) silver triflate-graphac gas chromatography column to produce [11C]methyl triflate.
Then, the [11C]methyl triflate was reacted
with 1 mg of norsertraline (3 mM) and 1 M
sodium hydroxide (3 mM) to produce [11C]
sertraline. The [11C]sertraline was purified
by high-performance liquid chromatography
(column: Waters XTerra RP-8, 10 × 250 mm,
10 mm; Waters, Milford, MA, USA; eluent:
EtOH 55% in 10 mM phosphate buffer at pH
7; flow rate: 3 ml/min). The specific activity
of [11C]sertraline was 577.2 ± 181.3 MBq.
The mean (range) amount of radiotracer
injected into subjects was 690.42 (569.8 –
832.5) MBq, and it contained less than 12.8
nmol of sertraline.
PET scan and serotonin
transporter SUV measurement
PET scans were performed in 2D mode
on the whole body scanner, ECAT Exact
47 (Siemens, Knoxville, TN, USA). Radiotracer was injected via a catheter placed in
the vein of the subject’s arm before the scan
started. After 690.42 MBq (range 569.8 –
832.5 MBq) of [11C]sertraline was administered, the scan was acquired for 90 min with
a variable frame duration (15 s × 8, 30 s ×
16, 60 s × 10, 240 s × 10, 300 s × 12). With
a filtered back projection, scanned images
were reconstructed as 128 × 128 × 47 matrices of 2.57 × 2.57 × 3.375 mm voxels. Eight
regions of interest were analyzed according
to a method previously reported [16]. These
included the cerebellum, thalamus, caudate
nucleus, cingulate, hippocampal formation,
putamen, temporal lobe and occipital lobe.
The standardized uptake values (SUV) in the
striatum were calculated and compared to
the reference region as a ratio (SUVr), as follows: SUVr = (SUV of the specific region)/
(SUV of the reference region). SUVr measurements were obtained between 50 and 90
min after [11C]sertraline injection.
To obtain accurate delineation of the
brain regions for data analysis, each subject underwent magnetic resonance imaging
(MRI; GE 3.0T VH/i SIGMA EXCIE E2M4,
T1-weighted, 3D, SPGR). MRI images were
0.94 × 0.94 × 1.00 mm pixel in size.
Pharmacokinetic analysis
On the 6th day of each treatment period,
an indwelling cannula was inserted into a
forearm vein, and blood samples (8 ml) were
collected at scheduled times: before (0 h),
and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 h
after the oral sertraline dose.
Individual pharmacokinetic parameters
were determined with the non-compartmental methods used in Phoenix® software (Pharsight Corporation, St. Louis, MO, USA). The
terminal elimination half-life (t1/2) was calculated from a linear regression of log-transformed serum concentrations over the time
course for each individual, where t1/2 = ln(2)/
lz. The area under the plasma concentrationtime curve over the dosing interval (24 h) at
steady-state (AUCt,ss) was calculated with the
linear-up and log-down trapezoidal method
on serum concentration-time curves. lz is the
terminal elimination rate constant. The accumulation ratios were calculated as 1/(1–elz·t).
Measurement of drug
concentrations
A rapid, sensitive, specific method was
employed for quantification of plasma sertraline. Fluoxetine was used as the internal standard (IS). The sample preparation involved
a simple liquid-liquid extraction procedure
[17, 25]. The extract was analyzed with high
227
A PET microdosing study with sertraline
Figure 1. Representative [11C]sertraline PET images of the human brain, before (baseline) and 24 h after
6-day administrations of sertraline at different doses in a typical subject. Bar represents a color-coded
scale of the range of standardized uptake values ratios (SUVr); (SUV of the specific region)/(SUV of the
reference region).
accuracy, precision and stability. The sertraline concentration was a linear function
over the range from 0.05 to 50 ng/ml, and
the lower limit of quantification (LLOQ)
in serum was 0.05 ng/ml. The accuracy for
the within- and between-run values ranged
from 87.17 to 110.05% and from 87.91 to
101.99%, respectively. The precision levels
for the within- and between-run values were
below 14.71 and 9.64%, respectively.
Statistical analysis
Figure 2. Activity concentration of [11C]sertraline
over time in the regions of interest at baseline in a
typical subject.
performance liquid chromatography coupled
to electrospray tandem mass spectrometry
(LC-MS/MS). The analyte and IS were separated on a C18 reversed phase column (Luna,
5 mm × 50 mm × 2.0 mm, Phenomenex Inc.,
Torrance, CA, USA), with a mobile phase
composed of acetonitrile (B) and 10 mM ammonium acetate (A) with 0.1% formic acid.
Separation proceeded by gradient elution
(10 – 45% B from 0 to 1.4 min, 90% B from
1.5 to 2.0 min, 10% B to 3 min). Quantitation
was performed in positive ion and multiple
reaction monitoring (MRM) mode. We monitored protonated precursor product ion transitions of m/z 306.2 → 275.2 for sertraline
and 310.6 → 148.4 for the IS. The method
was fully validated for selectivity, linearity,
Dose linearity was tested for Cmax,ss and
AUCt,ss by linear regression analysis to evaluate whether sertraline demonstrated dose-independent behavior [9]. Analysis of variance
(ANOVA) tests were used for comparisons
among dose-normalized Cmax,ss and AUCt,ss.
The Kruskal-Wallis test was performed for
comparisons among SUVr values in the putamen, cingulate, and caudate at baseline and
sertraline dose of 5 mg, 25 mg and 50 mg dosing. All significance levels (p < 0.05) were obtained from two-sided tests. Statistical analyses were performed with SPSS® 17.0 software
(SPSS Inc., Seoul, Korea) and SAS® 9.2 (SAS
Institute Inc., Cary, NC, USA).
Results
Subjects
Eleven volunteers were enrolled, and 1 subject dropped out the study; that subject withdrew informed consent before drug administration. Ten volunteers completed the study with
a mean age (range) of 27.5 (21.0 – 43.0) years,
228
Shin, Kim, Lim et al.
Figure 3. Mean serum concentration (SD) of sertraline in 10 healthy volunteers after 6-day oral administrations of sertraline at doses of 5, 25, or 50 mg/day. a: linear scale; b: semi-logarithmic scale.
Table 1. Standardized uptake value ratios (SUVr) in 10 healthy volunteers in the putamen, cingulate
and caudate nucleus after [11C]sertraline administration.
Regions of interest
Putamen
Cingulate
Caudate nucleus
Baseline
1.40 (0.17)
1.19 (0.13)
1.09 (0.20)
Sertraline
5 mg
1.36 (0.23)
0.96 (0.71)
1.09 (0.22)
Sertraline
25 mg
1.36 (0.16)
1.18 (0.14)
1.10 (0.17)
Sertraline
50 mg
1.41 (0.17)
1.19 (0.13)
1.11 (0.19)
χ 2*
p value*
1.574
0.824
0.072
0.665
0.844
0.995
Values are mean (SD). * The Kruskal-Wallis test was performed among baseline, sertraline 5 mg, 25 mg
and 50 mg treatment.
Table 2.
Pharmacokinetic results for 5, 25 and 50 mg doses of sertraline.
Parameters
Cmax,ss (ng/ml)
Cmax,ss/dose (ng/ml/mg)
AUCt,ss (ng × h/ml)
AUCt,ss/dose
(ng × h/ml/mg)
CLss/F (l/h)
tmax (h)†
t1/2 (h)
Accumulation ratio
Sertraline 5 mg
2.55 ± 1.03
0.51 ± 0.21
47.55 ± 21.03
Sertraline 25 mg Sertraline 50 mg
16.27 ± 7.20
37.28 ± 16.02
0.65 ± 0.27
0.75 ± 0.32
305.17 ± 139.82 681.62 ± 301.03
F value
29.66
1.84
27.58
p value*
< 0.001
0.179
< 0.001
9.51 ± 4.21
12.21 ± 5.59
13.63 ± 6.02
1.54
0.232
135.38 ± 88.41
6.0 (3.98 – 8.00)
36.7 ± 12.1
2.75 ± 0.71
143.15 ± 75.43
6.0 (4.0 – 8.0)
37.8 ± 8.34
2.81 ± 0.49
92.82 ± 55.98
6.0 (4.0 – 8.0)
39.1 ± 11.1
2.89 ± 0.65
1.08
0.70
0.13
0.13
0.353
0.503
0.353
0.881
Cmax,ss = maximum concentration at steady state; Cmax,ss/dose = dose normalized Cmax,ss; AUCt,ss = area
under the plasma concentration-time curve during the dosing interval (t = 24 h) at steady-state; AUCt,ss/
Dose = dose normalized AUCτ,ss; CLss/F = apparent clearance at steady- state; tmax = time at maximum
concentration; t1/2 = terminal elimination half-life, values (except tmax) represent the arithmetic mean ± SD
among 10 subjects. *ANOVA test was performed among 5 mg, 25 mg, 50 mg. †tmax values are presented
as the median (minimum – maximum).
mean weight (range) of 66.3 (64.4 – 79.5) kg,
and individual body weight values were within
80 – 120% of ideal body weight.
PET-standardized uptake values
Figure 1 shows the brain PET images of
a representative subject taken at baseline and
at the end of Periods 1 – 3. Further analysis (Figure 2) showed that the putamen had
the highest uptake of [11C]sertraline, and the
cingulate had the next highest uptake. These
results were consistent with results from a
previous study [24]. The SUVr values were
referenced to the SUV of the cerebellum
[21]. The main SUVr findings are presented
in Table 1.
Pharmacokinetics
All three doses achieved a mean peak
concentration at 6 h (range 3.98 – 8.0 h). For
A PET microdosing study with sertraline
5, 25 and 50 mg doses, the mean terminal
elimination half-lives were 36.7, 37.8 and
39.1 h, respectively (Table 2) (Figure 3); the
mean (SD) dose normalized Cmax,ss values
were 0.51 (0.21), 0.65 (0.29) and 0.75 (0.32)
mg/l/mg, respectively (p = 0.179); and the
dose normalized AUCt,ss values were 9.51
(4.21), 12.21 (5.59) and 13.63 (6.02) mg ×
h/l/mg, respectively (p = 0.232). Dose linearity in the Cmax,ss and AUCt,ss was assessed
with linear regression and expressed in terms
of 95% confidence intervals (CIs) of the intercept. For Cmax,ss and AUCt,ss, the CIs were
–8.54 to 4.64 (intercept: –1.95) and –156.4
to 92.3 (intercept: –32.0), respectively. The
mean accumulation ratios were between 2.75
and 2.89.
Safety
All subjects who received at least one
dose of the study drug were included in the
safety assessment (n = 10). A total of 12 adverse events (AEs) was reported in 6 of 10
subjects. All AEs were transient, and the subjects recovered spontaneously without intervention. All AEs were of mild intensity, and
the subjects showed no significant changes
in vital signs, ECGs, laboratory tests, or
physical examinations.
Discussion
We explored the potential of the microdose method by testing its predictions of sertraline biodistribution and pharmacokinetic
characteristics. We demonstrated that PET
analysis could predict the brain distribution
and that LC-MS/MS could predict the pharmacokinetics of low doses of sertraline. This
study described a microdosing method that
combined PET with a LC-MS/MS-based
pharmacokinetic assessment. The results
showed that sertraline was rapidly distributed in the brain and slowly eliminated. The region with the highest concentration was the
putamen and the region with the lowest concentration was the cerebellum. The results
were consistent with other PET studies of
sertraline [11, 28]. There was no significant
trend in the mean SUVr values measured at
steady state for dose increments of 5, 25 and
229
50 mg sertraline. A linear pharmacokinetic
profile was observed in the dose range of
5 – 50 mg of sertraline.
The PET results demonstrated that the
drug penetrated the BBB and reached the
expected region. Sertraline was distributed
throughout the brain within 20 min, and it
was highly distributed in the putamen, cingulate, and thalamus. Sertraline and other SSRIs
primarily target the 5-HT2A receptors, which
are highly expressed in the striatum which includes putamen and caudate in brain [20].
Our results also showed that little drug
was eliminated during the 90 min PET scan.
This might be related to physicochemical
properties of the radio-labeled ligand. Slow
elimination may result from a high affinity
or non-specific binding; for example, some
radioligands exhibit amine binding. SSRIs,
including fluoxetine, paroxetine, and sertraline have relatively high affinity for 5-HT
transporters; thus, they have been radiolabeled with 11C or 18F for use as radiotracers for PET. However, these tracers have
shown extensive lipophilicity, which resulted in high levels of nonspecific binding and
slow clearance rates. Among the mentioned
SSRIs, sertraline has the highest affinity to
sigma receptors (Ki = 57 nM) [22], which
are known to be present at high density in
the human cerebellum [18]. This may have
contributed to our observations of high nonspecific binding of sertraline and its slow
elimination. Thus, the interpretation of the
PET results requires an understanding of the
physicochemical properties of the radioligand. Moreover, the chemical structure and
metabolism of the drug should be considered
in the interpretation of the PET images.
The SUVr did not show a typical pattern
in this study. This may have been due to the
relatively high steady-state levels of sertraline, which may have saturated the transporters. On the other hand, down-regulation
of transporters may have resulted from the
consecutive sertraline doses. In a previous
study, after 4 days of multiple citalopram administration in rats, the transport rate (Vmax)
and ligand binding sites (Bmax) of serotonin
transporters were reduced by 38% and 53%,
respectively, compared to the control group
[15].
In a previous study, sertraline showed linear kinetics for a dose range of 50 – 200 mg,
230
Shin, Kim, Lim et al.
and a 0.1 ng/ml LLOQ value was achieved
with LC-MS/MS [13]. In the current study,
we obtained a lower LLOQ (0.05 ng/ml) for
sertraline. The pharmacokinetic analysis for
5 – 50 mg of sertraline demonstrated a linear
relationship between the doses and serum
concentrations. This linear PK profile, from
a low-dose to therapeutic doses supported
the validity of the microdosing approach, because a linear PK is crucial for extrapolating
the PK profile.
This study had some limitations. First,
we used a 90 min PET scan for acquiring
measurements for each period. This short
measurement period only provided limited
information on the distribution kinetics of
the drug and its time course. PET scans were
conducted at baseline and at 24 h after the
last dose was administered, because the
study aimed at investigating the distribution
at steady state and observe changes in brain
distributions with different dosages. We did
not perform more PET scans, because we
wanted to avoid exposing the volunteers to
excessive radiation, which might be incurred
with frequent PET scans. Second, the plasma
concentration of [11C]sertraline could have
been more accurately measured by AMS.
However, because the AMS method is costly
to setup and requires a radio-labeling process, current studies are increasingly using
the LC-MS/MS approach [31, 32]. Thus, development of a study design with LC-MS/
MS for microdosing was relevant in terms of
general accessibility.
In conclusion, this study provided information on the brain disposition and BBB
penetration of a CNS drug in healthy volunteers. We obtained linear PK characteristics,
which supported the extrapolation of the PK
profile from a low dose to a therapeutic dose
for microdosing. Sertraline was used as a
model of a CNS drug candidate, and the current results indicated that this method can be
applied to drug development. It will be important in future studies to consider several
factors that affect the interpretation of microdosing study results, including the expected
mechanism of action, the physicochemical
properties of the drug that might affect the
disposition pattern, the LLOQ of the assay
method, the safety and the accessibility of
the method. This study provided support for
using PET microdosing as a tool to investi-
gate the distribution of radio-labeled CNS
drug candidates. Further studies are needed
to establish more efficacious microdosing
strategies.
Acknowledgments
This study was supported by a grant from
the Korea Healthcare technology R&D Project, Ministry of Health and Welfare Affairs,
Republic of Korea (A070001). Kwang-Hee
Shin was supported by a training program
grant of the Korea Healthcare Technology
R&D Project, Ministry for Health and Welfare Affairs, Republic of Korea (A070001).
The authors thank Jin-Woo Park, Jun-Yul
Bae, Seoul National University College of
Medicine, for assistance in manuscript preparation.
Financial disclosure
This study was supported by a grant from
the Korean Healthcare Technology R&D
Project, Ministry of Health and Welfare Affairs, Republic of Korea (A070001). The
authors declare no conflict of interest to disclose.
Clinical trial registry: http://clinicaltrials.
gov, NCT00969852.
References
[1]
[2]
[3]
European Medicines Agency. Position paper on
non-clinical safety studies to support clinical trials
with a single microdose (EMA web site) Available
at: http://www.ema.europa.eu/docs/en_GB/document_
library/Scientific_guideline/2009/10/
WC500003979.pdf. Aceessed April 18, 2011.
International conference on harmonisation of tech
nical requirements for registration of pharma
ceuticals for human use (ICH). ICH harmonised
tripartite guideline: Guideline for good clinical
practice E6(R1) (ICH Web site) Available at:
http://www.ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Efficacy/E6_R1/Step4/
E6_R1__Guideline.pdf. Aceessed April 18, 2011.
International conference on harmonisation of tech
nical requirements for registration of pharma
ceuticals for human use (ICH Web site). Available
at: http://www.ich.org/fileadmin/Public_Web_Site/
ICH_Products/Guidelines/Safety/M3_R2/
Presentation/A._Jacobs_ICH_M3_R2__
presentation_to_the_GCG_and_the_Tokyo_
Symposium_6-09.pdf. Aceessed April 18, 2011.
231
A PET microdosing study with sertraline
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
U.S. Department of Health and Human Services.
FDA, Guidance for Industry, Investigators and
Reviewers, Exploratory IND studies (FDA web
site). Available at: http://www.fda.gov/downloads
/Drugs/GuidanceCompli anceRe gula toryIn formation/Guidances/ucm078933.pdf. Aceessed April
18, 2011.
World Medical Association (WMA). World Medical Association Declaration of Helsinki – Ethical
principles for medical research involving human
subjects. (WMA Web site). Available at: http://
www.wma.net/en/30publications/10policies/
b3/17c.pdf. Aceessed April 18, 2011.
Balani SK, Nagaraja NV, Qian MG, Costa AO,
Daniels JS, Yang H, Shimoga PR, Wu JT, Gan LS,
Lee FW, Miwa GT. Evaluation of microdosing to
assess pharmacokinetic linearity in rats using
liquid chromatography-tandem mass spectrometry. Drug Metab Dispos. 2006; 34: 384-388.
PubMed
Bauer M, Langer O, DalBianco P, Karch R,
Brunner M, Abrahim A, Lanzenberger R, Hof
mann A, Joukhadar C, Carminati P, Ghirardi O,
Piovesan P, Forloni G, Corrado ME, Lods N,
Dudczak R, Auff E, Kletter K, Müller M. A
positron emission tomography microdosing study
with a potential antiamyloid drug in healthy
volunteers and patients with Alzheimer’s disease.
Clin Pharmacol Ther. 2006; 80: 216-227.
doi:10.1016/j.clpt.2006.05.007 PubMed
Bergström M, Grahnén A, Långström B. Positron
emission tomography microdosing: a new concept
with application in tracer and early clinical drug
development. Eur J Clin Pharmacol. 2003; 59:
357-366. PubMed doi:10.1007/s00228-0030643-x
Bonate PL. Pharmacokinetics in Drug Development
Volume 1: Clinical Study Design and Analysis.
Arlington: American Association of Pharmaceutical
Scientists; 2004. p. 363-381.
Comar D, Crouzel C, Mazière B. Positron emission tomography: standardisation of labelling
procedures. Int J Rad Appl Instrum (A). 1987; 38:
doi:10.1016/0883-2889(87)90121-3
587-596.
PubMed
DeVane CL, Liston HL, Markowitz JS. Clinical
pharmacokinetics of sertraline. Clin Pharmacokinet.
2002;
41:
1247-1266.
doi:10.2165/00003088-200241150-00002
PubMed
Garner RC. Accelerator mass spectrometry in
pharmaceutical research and development – a
new ultrasensitive analytical method for isotope
measurement. Curr Drug Metab. 2000; 1: 205213. doi:10.2174/1389200003339054 PubMed
Goodnick PJ. Pharmacokinetic optimisation of
therapy with newer antidepressants. Clin Pharmacokinet.
1994;
27:
307-330.
doi:10.2165/00003088-199427040-00005
PubMed
Gründer G, Yokoi F, Offord SJ, Ravert HT,
Dannals RF, Salzmann JK, Szymanski S, Wilson
PD, Howard DR, Wong DF. Time course of
5-HT2A receptor occupancy in the human brain
after a single oral dose of the putative antipsychotic
drug MDL 100,907 measured by positron
emission tomography. Neuropsychopharmacology.
[15]
[16].
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
1997; 17: 175-185. PubMed doi:10.1016/S0893133X(97)00044-4
Horschitz S, Hummerich R, Schloss P. Downregulation of the rat serotonin transporter upon
exposure to a selective serotonin reuptake inhibitor. Neuroreport. 2001; 12: 2181-2184.
doi:10.1097/00001756-200107200-00027
PubMed
Huang Y, Hwang DR, Narendran R, Sudo Y,
Chatterjee R, Bae SA, Mawlawi O, Kegeles LS,
Wilson AA, Kung HF, Laruelle M, Comparative
evaluation in nonhuman primates of five PET
radiotracers for imaging the serotonin transporters:
[11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]
DAPA, and [11C]AFM. Journal of cerebral blood
flow and metabolism: official journal of the
International Society of Cerebral Blood Flow and
Metabolism 2002; 22: 1377-1398.
Jain DS, Sanyal M, Subbaiah G, Pande UC,
Shrivastav P. Rapid and sensitive method for the
determination of sertraline in human plasma using
liquid chromatography-tandem mass spectrometry
(LC-MS/MS). J Chromatogr B Analyt Technol
Biomed Life Sci. 2005; 829: 69-74. doi:10.1016/j.
jchromb.2005.09.035 PubMed
Jansen KL, Faull RL, Dragunow M, Leslie RA.
Autoradiographic distribution of sigma receptors
in human neocortex, hippocampus, basal ganglia,
cerebellum, pineal and pituitary glands. Brain
Res. 1991; 559: 172-177. doi:10.1016/00068993(91)90303-D PubMed
Lasne MC, Pike VW, Turton DR. The radiosynthesis of [N-methyl-11C]-sertraline. Int J Rad
Appl Instrum [A]. 1989; 40: 147-151.
doi:10.1016/0883-2889(89)90190-1 PubMed
Marek GJ, Carpenter LL, McDougle CJ, Price
LH. Synergistic action of 5-HT2A antagonists and
selective serotonin reuptake inhibitors in neuro
psychiatric disorders. Neuropsychopharmacology. 2003; 28: 402-412. doi:10.1038/sj.
npp.1300057 PubMed
Meyer JH, Wilson AA, Ginovart N, Goulding V,
Hussey D, Hood K, Houle S. Occupancy of serotonin transporters by paroxetine and citalopram
during treatment of depression: a [(11)C]DASB
PET imaging study. Am J Psychiatry. 2001; 158:
doi:10.1176/appi.ajp.158.11.1843
1843-1849.
PubMed
Narita N, Hashimoto K, Tomitaka S, Minabe Y.
Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat
brain. Eur J Pharmacol. 1996; 307: 117-119.
doi:10.1016/0014-2999(96)00254-3 PubMed
Pardridge WM. Blood-brain barrier delivery.
Drug Discov Today. 2007; 12: 54-61.
doi:10.1016/j.drudis.2006.10.013 PubMed
Parsey RV, Kent JM, Oquendo MA, Richards MC,
Pratap M, Cooper TB, Arango V, Mann JJ. Acute
occupancy of brain serotonin transporter by
sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry. 2006;
59: 821-828. doi:10.1016/j.biopsych.2005.08.010
PubMed
Patel BN, Sharma N, Sanyal M, Shrivastav PS.
Analysis of second-generation antidepressant drug,
sertraline and its active metabolite, N-desmethyl
sertraline in human plasma by a sensitive and
selective liquid chromatography-tandem mass
Shin, Kim, Lim et al.
[26]
[27]
[28]
[29]
[30]
[31]
[32]
spectrometry method. J Chromatogr B Analyt
Technol Biomed Life Sci. 2009; 877: 221-229.
doi:10.1016/j.jchromb.2008.12.008 PubMed
Sandhu P, Vogel JS, Rose MJ, Ubick EA, Brunner
JE, Wallace MA, Adelsberger JK, Baker MP,
Henderson PT, Pearson PG, Baillie TA. Evaluation of microdosing strategies for studies in
preclinical drug development: demonstration of
linear pharmacokinetics in dogs of a nucleoside
analog over a 50-fold dose range. Drug Metab
Dispos. 2004; 32: 1254-1259. doi:10.1124/
dmd.104.000422 PubMed
Taylor EM. The impact of efflux transporters in
the brain on the development of drugs for CNS
disorders. Clin Pharmacokinet. 2002; 41: 81-92.
doi:10.2165/00003088-200241020-00001
PubMed
Voineskos AN, Wilson AA, Boovariwala A, Sagrati
S, Houle S, Rusjan P, Sokolov S, Spencer EP,
Ginovart N, Meyer JH. Serotonin transporter
occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder
measured with [11C]DASB positron emission
tomography. Psychopharmacology (Berl). 2007;
193: 539-545. doi:10.1007/s00213-007-0806-z
PubMed
Wagner CC, Simpson M, Zeitlinger M, Bauer M,
Karch R, Abrahim A, Feurstein T, Schütz M,
Kletter K, Müller M, Lappin G, Langer O. A
combined accelerator mass spectrometry-positron
emission tomography human microdose study
with 14C- and 11C-labelled verapamil. Clin Pharmacokinet.
2011;
50:
111-120.
doi:10.2165/11537250-000000000-00000
PubMed
Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol.
1991; 6 (Suppl 2): 11-21. doi:10.1097/00004850199112002-00004 PubMed
Yamane N, Takami T, Tozuka Z, Sugiyama Y,
Yamazaki A, Kumagai Y. Microdose clinical trial:
quantitative determination of nicardipine and
prediction of metabolites in human plasma. Drug
Metab Pharmacokinet. 2009; 24: 389-403.
doi:10.2133/dmpk.24.389 PubMed
Yamazaki A, Kumagai Y, Yamane N, Tozuka Z,
Sugiyama Y, Fujita T, Yokota S, Maeda M.
Microdose study of a P-glycoprotein substrate,
fexofenadine, using a non-radioisotope-labelled
drug and LC/MS/MS. J Clin Pharm Ther. 2010;
35:
169-175.
doi:10.1111/j.1365-2710.2009.01159.x PubMed
232